Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 1.00 |
| ▸ | TFEB | P19484 | 1/20 | 0.72 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744350 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBLY96CYP1A1CYP1A2 | |
| SCHEMBL14571866 | 0.89 | NFE2L2 (0.80) | NFE2L2TFEBLY96CYP1A1CYP1A2 | |
| SCHEMBL16382579 | 0.89 | NFE2L2 (0.78) | NFE2L2TFEBLY96CYP1A1CYP1A2 | |
| SCHEMBL6776487 | 0.88 | NFE2L2 (0.79) | NFE2L2TFEBCYP1A1CYP1A2CYP2D6 | |
| SCHEMBL457033 | 0.88 | NFE2L2 (0.79) | NFE2L2TFEBCYP1A1CYP1A2CYP2D6 | |
| SCHEMBL14950768 | 0.88 | NFE2L2 (0.79) | NFE2L2TFEBLY96CYP1A1CYP1A2 | |
| SCHEMBL1056670 | 0.88 | NFE2L2 (0.79) | NFE2L2TFEBCYP1A1CYP1A2CYP2D6 | |
| SCHEMBL7438631 | 0.87 | NFE2L2 (0.77) | NFE2L2CYP1A1CYP1A2CYP2D6ALOX5 | |
| SCHEMBL5598884 | 0.87 | NFE2L2 (1.00) | NFE2L2CYP1A1CYP1A2CYP2D6ALOX5 | |
| SCHEMBL7438622 | 0.87 | NFE2L2 (0.77) | NFE2L2CYP1A1CYP1A2CYP2D6ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | claimed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | NFE2L2 109/4885TFEB 293/4885LY96 2884/4885 |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | NFE2L2 75/4885TFEB 19/4885LY96 1750/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | NFE2L2 75/4885TFEB 19/4885LY96 1750/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | NFE2L2 75/4885TFEB 19/4885LY96 1750/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | NFE2L2 5/4885TFEB 346/4885LY96 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.